following a full submission:
pembrolizumab (Keytruda®) is accepted for restricted use within NHS Scotland.
Indication under review: as monotherapy for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.
SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule.
In a phase III study, pembrolizumab increased progression free survival compared with an antibody-drug conjugate medication in patients with relapsed/refractory classical Hodgkin lymphoma who were ineligible for or had relapsed after ASCT.
This advice applies only in the context of an approved NHS Scotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- pembrolizumab (Keytruda)
- SMC ID:
- SMC2380
- Indication:
As monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.
- Pharmaceutical company
- Merck Sharp & Dohme Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 08 November 2021